<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362037</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0255</org_study_id>
    <nct_id>NCT00362037</nct_id>
  </id_info>
  <brief_title>I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy</brief_title>
  <official_title>Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in&#xD;
           non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients).&#xD;
&#xD;
        -  To emphasize and to evaluate the benefit of Irbesartan in the reduction of left&#xD;
           ventricular mass index in hypertensive patients with left ventricular hypertrophy.&#xD;
&#xD;
        -  To demonstrate safety of Irbesartan in this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in BP to target values according to the ESC 2003 Hypertension Guidelines</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in left ventricular hypertrophy from baseline values to week 36.</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any side effect leading to treatment discontinuation.</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">281</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan (Aprovel)</intervention_name>
    <description>Aprovel (150 &amp; 300mg) &amp; CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with proven mild to moderate Hypertension.&#xD;
&#xD;
          -  Patients must have left ventricular mass index &gt; 130g/m2 in men, &gt; 100g/m2 in women,&#xD;
             as evidenced by echocardiography before inclusion.&#xD;
&#xD;
          -  Newly diagnosed &quot;naïve&quot; hypertensive patients (no prior treatment for hypertension).&#xD;
             OR,&#xD;
&#xD;
          -  Patients who were receiving antihypertensive agents (maximum two agents including one&#xD;
             diuretic) with blood pressure targets achieved, yet, in the investigator's opinion,&#xD;
             those patients would benefit more from switching to the study medication. These&#xD;
             patients will undergo a wash out period for not less than 7 days prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hypertension (Systolic BP ≥ 180 mm Hg or Diastolic BP ≥ 110 mm Hg).&#xD;
&#xD;
          -  Patients with left ventricular ejection fraction &lt; 45%.&#xD;
&#xD;
          -  Patients with severe left ventricular hypertrophy.&#xD;
&#xD;
          -  Patients with known secondary hypertension (for another cause other than type 2&#xD;
             Diabetes Mellitus).&#xD;
&#xD;
          -  Diabetic patients with HbA1c &gt; 10%.&#xD;
&#xD;
          -  Significant chronic renal impairment (Serum creatinine &gt; 2.0 mg/dL).&#xD;
&#xD;
          -  Significant liver disease as shown by SGPT/SGOT (ALT/AST) &gt; 2.5 times the upper limit&#xD;
             of the normal range.&#xD;
&#xD;
          -  Currently pregnant or lactating females.&#xD;
&#xD;
          -  Women of childbearing potential not protected by effective contraceptive method of&#xD;
             birth control and/or who are unwilling or unable to be tested for pregnancy.&#xD;
&#xD;
          -  Any patient who is in need for a combination antihypertensive therapy from the start&#xD;
             (from the medical point of view of his/her physician).&#xD;
&#xD;
          -  Known hypersensitivity to irbesartan, other ARBs(Angiotensin Receptor Blockers),&#xD;
             hydrochlorothiazide, or other thiazide diuretics.&#xD;
&#xD;
          -  Patients with malignancy during the past 5 years, known collagen disease or severe&#xD;
             cardiac, cerebrovascular or gastric disease.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mosaad I Morsi, MBBCh, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <last_update_submitted>May 27, 2011</last_update_submitted>
  <last_update_submitted_qc>May 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

